44 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.
Indiana University School of Medicine
Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.
Sanford-Burnham Medical Research Institute
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
Indiana University School of Medicine
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
University of Utah
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Shandong University
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.
Indiana University School of Medicine
Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors.
Peking Union Medical College
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Indiana University School of Medicine
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.
University of Southern California
Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors.
Indiana University
Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.
Indiana University School of Medicine
Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase.
Columbia University
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Indiana University School of Medicine
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Sanford-Burnham Medical Research Institute
Oxidative inactivation of the lymphoid tyrosine phosphatase mediated by both general and active site directed NO donors.
University of Utah
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Indiana University School of Medicine
Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy.
Shandong University
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases.
Purdue University
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.
Eli Lilly
Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors.
Abbott Laboratories
Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets.
Shandong University
Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.
Purdue University
A chalcone derivative binds a putative allosteric site of YopH: Inhibition of a virulence factor of Yersinia.
Universidade Federal De Santa Catarina
Synthetic thiosemicarbazones as a new class of Mycobacterium tuberculosis protein tyrosine phosphatase A inhibitors.
Universidade Federal De Santa Catarina
Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
Universidade Federal De Santa Catarina
Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
Merck Patent
Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
Bristol-Myers Squibb
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
Oged
Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
Millennium Pharmaceuticals
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.
Sanford-Burnham Medical Research Institute
Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis.
The Scripps Research Institute
Naturally Occurring Pentacyclic Triterpenes as Inhibitors of Glycogen Phosphorylase: Synthesis, Structure-Activity Relationships, and X-ray Crystallographic Studies.
China Pharmaceutical University
Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
Gsk
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
Gsk
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.
Millennium Pharmaceuticals